Republic of the Philippines
Department of Health
METRO MANILA CENTER FOR HEALTH DEVELOPMENT

SUPPLEMENTAL/ BID BULLETIN NO. 1

IB 2022 – 070
PROCUREMENT OF 816,604 VIALS OF MEDROXYPROGESTERONE ACETATE SUSPENSION

This Supplemental/Bid Bulletin No. 1 is being issued to revise provisions/specifications in the Bidding Documents for a forecited project:

Revision and clarification to provisions/specifications in the Bidding Documents:	
FROM	**TO**
150mg/ml, 1ml vial injectable	150mg/ml, 1ml vial injectable as Acetate Suspension
Delivery Schedule: Forty-five (45) Calendar days	Delivery Schedule: Forty-five (45) to Sixty (60) Calendar days

Bidders are advised to use the following attached forms and submit together with all required documents for the submission of bids on 19th day of July 2022, 9:00 AM:

This Supplemental/Bid Bulletin No. 1 shall form an integral part of the Bidding Documents. All other provisions indicated in the bidding documents which are not affected by this Supplemental/Bid Bulletin No. 1 shall remain in effect.

For guidance and information of all concerned.

Issued this 12th day of July 2022 in MMCHD

Approved by:

ALELI ANNIE GRACE P. SUDIACAL, MD, MPH
Director III / BAC Chairperson

Republic of the Philippines
Department of Health
METRO MANILA CENTER FOR HEALTH DEVELOPMENT

Republic of the Philippines Department of Health Metro Manila Center for Health Development TECHNICAL SPECIFICATIONS			
Item No. 1	**PROCUREMENT OF 816,604 VIALS OF MEDROXYPROGESTERONE ACETATE SUSPENSION**	Qty./Unit	**816,604 VIALS**
Name of Manufacturer:		Country of Origin	
Brand:		Model: (if applicable)	
ABC: **P 24,498,120.00**			
PURCHASER'S SPECIFICATION		STATEMENT OF COMPLIANCE	
SPECIFICATIONS: 150mg/ml, 1ml vial injectable as Acetate Suspension			
UPON DELIVERY THE FOLLOWING MUST BE COMPLIED: **Shelf Life:** Must be fresh commercial stock with a total shelf life of thirty six (36) months upon manufacture and 34 months upon delivery. **Packaging Instructions:** Standard packaging of the manufacturer as approved by PFDA including product insert or encryption/ imprint inside the box. **Labelling Instructions:** Standard labelling instruction as approved by PFDA pursuant to Administrative Order No. 2016-0008 **In addition to the labelling requirements of FDA:** a. On each vial the following should be imprinted or stickered with non-removable or permanent sticker or label that is binding and with residue and tearing if removed: b. On each small box and corrugated carton, the following should be imprinted or stickered with non-removable or permanent sticker or label that is binding and will leave residue and tearing if removed: **Philippine Government Property-Department of Health** **NOT FOR SALE**			

Date of Manufacture: _____ Date of Expiry: _____ Batch/Lot No. _____ Delivery Schedule: Forty-five (45) to Sixty (60) Calendar days Place of Delivery: DOH-MMCHD Pasig Warehouse	
D. <u>Additional Requirement to be submitted by the Single/Lowest Calculated Bidder (SCB/LCB) as part of post qualification</u>: 1. One (1) original sample of manufacturer's product to be submitted and returned after evaluation. The sample submitted and approved during the evaluation shall be the same item to be delivered upon award of contract. Prototype of the labelling instruction must be part of the sample submitted however, the technical specifications of the labelling instruction of the product must be complied upon delivery.	